Mcp-1 splice variants and methods of using same
OwnerZurit Levin, Amir Toporik +5inventors
InventorsZurit Levin, Amir Toporik, Michal Ayalon-Soffer, Iris Hecht, Merav Beiman, Dani Eshel, Tali Handelsman
Life of this patent
Estimating the term…
Loading patent…
OwnerZurit Levin, Amir Toporik +5inventors
InventorsZurit Levin, Amir Toporik, Michal Ayalon-Soffer, Iris Hecht, Merav Beiman, Dani Eshel, Tali Handelsman
Estimating the term…
Novel MCP-1 splice variant polypeptides and polynucleotides encoding same are provided. Also provided are pharmaceutical compositions comprising the splice variant polypeptides and polynucleotides, vectors and host cells comprising same. The compositions of the present invention are useful to treat various MCP-1 related disorders as well as for diagnosing, determining predisposition and/or prognosis of various disorders.
1-35. (canceled)
An isolated polynucleotide coding for a fusion protein comprising a splice variant of MCP-1, wherein said splice variant lacks the predicted C terminal alpha helix of the known human MCP-1 (SEQ ID NO:8), further comprising a polynucleotide having a sequence coding for an immunoglobulin moiety that comprises a constant region of an immunoglobulin.
An isolated chimeric polypeptide having a first amino acid sequence being at least about 95% homologous to amino acids 1-64 of S71513_P1 (SEQ ID NO:9), an amino acid M, and a second amino acid sequence selected from an immunoglobulin moiety that comprises a constant region of an immunoglobulin and an isolated Fc moiety, wherein said first amino acid sequence, said amino acid M and said second amino acid sequence are contiguous and in a sequential order.
An isolated chimeric polypeptide having a first amino acid sequence being at least about 95% homologous to amino acids 1-41 of mature MCP-1 variant (SEQ ID NO:35), an amino acid M, and a second amino acid selected from an immunoglobulin moiety that comprises a constant region of an immunoglobulin and an isolated Fc moiety, wherein said first amino acid sequence, said amino acid M and said second amino acid sequence are contiguous and in a sequential order, wherein optionally said first amino acid sequence comprises at least one of the following mutations:
An isolated polypeptide having an amino acid sequence according to SEQ ID NO:9 with a point mutation selected from Y51L and R53V or both.
Dependencies are inferred from the claim text.